Literature DB >> 10499201

Clinical and electrophysiological studies in vincristine induced neuropathy.

P K Pal1.   

Abstract

Eighteen patients of lymphoma, treated with vincristine (VCR) were assessed clinically and electrophysiologically before and for 3 months after therapy. The earliest evidence of neuropathy was impaired ankle jerk (around 2 weeks) and the earliest symptom was paraesthesia (by 4-5 weeks). At the end of the study, all the patients had absent ankle jerks and 75% had sensory symptoms and/or signs, the most frequent being impaired vibration sensation (62.5%). Motor abnormalities were much less common (18.7%) and constipation (62.5%) was the only autonomic manifestation. Concentric needle electromyography showed evidence of denervation (46.7%), especially in the small muscles of hand. Conduction studies showed prolonged mean distal latencies, decreased mean amplitudes of compound muscle action potentials, with almost unchanged conduction velocities. However, no conduction block was noted and F-wave studies were normal. During early weeks, in spite of impaired absent ankle jerks, H reflex was elicitable in the majority. However, later 56.2% had absent H reflex. The present study concludes that vincristine produces a distal symmetrical sensorimotor neuropathy, predominantly involving the large diameter fibers in the early stages. Electrophysiological studies characterize it as a distal axonopathy. However it is dependent on the dose of VCR and the duration of therapy: though in the usual doses it does produce neuropathy, it is rarely disabling in the early months.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10499201

Source DB:  PubMed          Journal:  Electromyogr Clin Neurophysiol        ISSN: 0301-150X


  21 in total

1.  Increased risk of vincristine neurotoxicity associated with low CYP3A5 expression genotype in children with acute lymphoblastic leukemia.

Authors:  Akinbode Egbelakin; Michael J Ferguson; Emily A MacGill; Amalia S Lehmann; Ariel R Topletz; Sara K Quinney; Lang Li; Kevin C McCammack; Stephen D Hall; Jamie L Renbarger
Journal:  Pediatr Blood Cancer       Date:  2010-11-11       Impact factor: 3.167

2.  Exploring the potential effect of Ocimum sanctum in vincristine-induced neuropathic pain in rats.

Authors:  Gurpreet Kaur; Amteshwar Singh Jaggi; Nirmal Singh
Journal:  J Brachial Plex Peripher Nerve Inj       Date:  2010-01-25

3.  Vincristine-induced neuropathy in rat: electrophysiological and histological study.

Authors:  Feras M H Ja'afer; Farqad B Hamdan; Faiq H Mohammed
Journal:  Exp Brain Res       Date:  2006-05-31       Impact factor: 1.972

4.  Incidence of chemotherapy-induced peripheral neuropathy within 12 weeks of starting neurotoxic chemotherapy for multiple myeloma or lymphoma: a prospective, single-center, observational study.

Authors:  Veronica B Ajewole; James E Cox; Joshua T Swan; Soumya G Chikermane; Beverly Lamoth; Tomona Iso; Laura O Okolo; Christen L Ford; Amy M Schneider; Eleanor C Hobaugh; Kelty R Baker
Journal:  Support Care Cancer       Date:  2019-07-29       Impact factor: 3.603

5.  Glutamic acid not beneficial for the prevention of vincristine neurotoxicity in children with cancer.

Authors:  Scott M Bradfield; Eric Sandler; Thomas Geller; Roy N Tamura; Jeffrey P Krischer
Journal:  Pediatr Blood Cancer       Date:  2014-12-24       Impact factor: 3.167

6.  Association of an inherited genetic variant with vincristine-related peripheral neuropathy in children with acute lymphoblastic leukemia.

Authors:  Barthelemy Diouf; Kristine R Crews; Glen Lew; Deqing Pei; Cheng Cheng; Ju Bao; Jie J Zheng; Wenjian Yang; Yiping Fan; Heather E Wheeler; Claudia Wing; Shannon M Delaney; Masaaki Komatsu; Steven W Paugh; Joseph Robert McCorkle; Xiaomin Lu; Naomi J Winick; William L Carroll; Mignon L Loh; Stephen P Hunger; Meenakshi Devidas; Ching-Hon Pui; M Eileen Dolan; Mary V Relling; William E Evans
Journal:  JAMA       Date:  2015-02-24       Impact factor: 56.272

Review 7.  Chemotherapy-induced peripheral neurotoxicity.

Authors:  Guido Cavaletti; Paola Marmiroli
Journal:  Nat Rev Neurol       Date:  2010-11-09       Impact factor: 42.937

Review 8.  Peripheral neuropathies from chemotherapeutics and targeted agents: diagnosis, treatment, and prevention.

Authors:  Wolfgang Grisold; Guido Cavaletti; Anthony J Windebank
Journal:  Neuro Oncol       Date:  2012-09       Impact factor: 12.300

9.  Lack of neuroprotection by an ACTH (4-9) analogue. A randomized trial in patients treated with vincristine for Hodgkin's or non-Hodgkin's lymphoma.

Authors:  S Koeppen; C C P Verstappen; R Körte; M E Scheulen; D Strumberg; T J Postma; J J Heimans; P C Huijgens; B Kiburg; K Renzing-Köhler; H C Diener
Journal:  J Cancer Res Clin Oncol       Date:  2004-01-16       Impact factor: 4.553

10.  An Inherited Genetic Variant in CEP72 Promoter Predisposes to Vincristine-Induced Peripheral Neuropathy in Adults With Acute Lymphoblastic Leukemia.

Authors:  W Stock; B Diouf; K R Crews; D Pei; C Cheng; K Laumann; S J Mandrekar; S Luger; A Advani; R M Stone; R A Larson; W E Evans
Journal:  Clin Pharmacol Ther       Date:  2016-11-16       Impact factor: 6.875

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.